Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2026 Feb;107(2):559-566.
doi: 10.1002/ccd.70383. Epub 2025 Nov 30.

Antithrombotic Therapy Selection and Association With Clinical Outcomes Following Valve-in-Valve Transcatheter Aortic Valve Replacement

John D'Angelo  1 , Hiroki Ueyama  1 , Krishan Patel  1 , Vasilis Babaliaros  1 , Adam Greenbaum  1 , Isida Byku  1 , Chandan Devireddy  1 , George Hanzel  1 , Brent Keeling  2 , Gaetano Paone  2 , Patrick Gleason  1 , Joe Xie  1
Affiliations
Comparative Study

Antithrombotic Therapy Selection and Association With Clinical Outcomes Following Valve-in-Valve Transcatheter Aortic Valve Replacement

John D'Angelo et al. Catheter Cardiovasc Interv. 2026 Feb.

Abstract

Background: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is being performed frequently for patients with bioprosthetic aortic valve (AV) degeneration. There is little guidance on appropriate antithrombotic selection after ViV TAVR. We aimed to analyze the impact of different antithrombotic strategies on AV hemodynamics and clinical outcomes following ViV TAVR.

Methods: Consecutive patients who underwent ViV TAVR at our center from January 1, 2019, to June 30, 2023, were included. Patients were divided into antiplatelet plus anticoagulant (AP + AC) or antiplatelet (AP) only groups based on the therapies prescribed on discharge. AV hemodynamics at discharge, 1 month, and 1 year, along with 1-year clinical outcomes, were compared between AP + AC and AP groups.

Results: This study included 104 patients with 74 patients (71.2%) in the AP + AC group and 30 patients (28.8%) in the AP group. Atrial fibrillation history (p = 0.003) was associated with AP + AC whereas GI bleeding history (p = 0.01) was associated with AP alone. There was no significant difference in antithrombotic therapy selection by TAVR type, but patients without a pre-existing indication for AC were more often discharged on AP + AC after receiving smaller diameter Sapien valves (p = 0.036). Additionally, patients were discharged on AP + AC more often if they required leaflet modification during TAVR (p = 0.043). There were no significant differences in AV gradients or clinical outcomes between antithrombotic strategies throughout follow-up.

Conclusions: Anticoagulation was used more often than AP alone following ViV TAVR, but there were no significant differences in AV hemodynamics by echocardiography or clinical outcomes between antithrombotic groups through 1 year of follow-up.

Keywords: ViV TAVR; antithrombotic therapies; structural heart.

PubMed Disclaimer

References

    1. C. M. Otto, R. A. Nishimura, R. O. Bonow, et al., “2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 143, no. 5 (2021): 35, https://doi.org/10.1161/CIR.0000000000000932.
    1. A. Vahanian, F. Beyersdorf, F. Praz, et al., “2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease,” European Heart Journal 43, no. 7 (2022): 561–632, https://doi.org/10.1093/eurheartj/ehab395.
    1. J. Rodés‐Cabau, J. B. Masson, R. C. Welsh, et al., “Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon‐Expandable Valve,” JACC Cardiovascular Interventions 10, no. 13 (2017): 1357–1365, https://doi.org/10.1016/j.jcin.2017.04.014.
    1. V. J. Nijenhuis, N. Bennaghmouch, M. Hassell, et al., “Rationale and Design of Popular‐TAVI: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation,” American Heart Journal 173 (2016): 77–85, https://doi.org/10.1016/j.ahj.2015.11.008.
    1. T. Chakravarty, A. Patel, S. Kapadia, et al., “Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement,” Journal of the American College of Cardiology 74, no. 9 (2019): 1190–1200, https://doi.org/10.1016/j.jacc.2019.06.058.

Publication types

MeSH terms

LinkOut - more resources